Very few young adults — members of Generation Z — are taking part in clinical trials and health studies in the UK. Experts warn that this could have long-term consequences for their health.
Mikolaj Laszkiewicz
Mikolaj Laszkiewicz
An experienced journalist and editor passionate about new technologies, computers, and scientific discoveries. He strives to bring a unique perspective to every topic. A law graduate.
Amazon One Medical has introduced a new pay-per-visit pediatric care service. Parents can now access text consultations starting at $29 and video visits from $49.
Finnish company Oura, known for its health-monitoring smart rings, has raised $900 million in a new funding round led by Fidelity Management & Research Company (FMR Co.). The deal brings Oura’s valuation to $11 billion.
Nvidia has announced that the DGX Spark, its new compact AI computer boasting a staggering 1-petaflop performance, is now available for order. Priced at $4,000, it’s designed to fit comfortably on a desk.
Scientists at the University of Massachusetts Amherst have developed the first artificial neuron capable of directly “communicating” with living cells — all without the need for any external signal amplification devices.
The U.S. Food and Drug Administration (FDA) has announced the most serious type of market recall (Class I) for Impella heart pump controllers manufactured by a company owned by Johnson & Johnson, citing discovered cybersecurity flaws.
The U.S. Senate has passed an amendment to the defense budget bill banning federal funding for projects involving Chinese biotechnology companies deemed a threat to national security.
OpenAI and Broadcom have entered into a partnership that will result in the first dedicated AI chips in OpenAI’s history. The company aims to reduce its reliance on external chip manufacturers — and the market response has been overwhelmingly positive.
The European Commission has unveiled a new program, Apply AI, which includes €1 billion in funding to accelerate the adoption of artificial intelligence across strategic sectors of the economy.
Novo Nordisk, the Danish giant known for its groundbreaking obesity drugs, has announced the acquisition of Akero Therapeutics for an astonishing $5.2 billion. The main goal behind the deal is access to one of the most promising drugs for MASH (Metabolic Dysfunction-Associated Steatohepatitis).